Autopsy report · NCT00431340

A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma

“Terminated due to dose limiting toxicity”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 3 months before it stopped.
• 4 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Valerio Therapeutics

Sponsor type

Industry

Conditions

Multiple Myeloma

Interventions

PXD101

Participants

4

Sites

3

Countries

United States

Trials that died the same way

• Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer
  “Terminated due to unacceptable toxicity” (85% match in meaning)
• Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult Patients
  “The study has been prematurely terminated due to the onset of 2 dose limiting toxicities in 2 patients.” (79% match in meaning)
• A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
  “The Sponsor terminated the study due to early dose-limiting toxicities.” (77% match in meaning)
• Safety Study of Bevacizumab (Avastin) With Thoracic Radiation in Non-small Cell Cell Lung Cancer
  “Study terminated due to toxicity” (77% match in meaning)
• GSK2983559 First Time in Human Study
  “Terminated due to non clinical toxicology findings and reduced safety margins.” (74% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.